Textures of the Future with iNewtritioninewtrition
Texture plays a huge role in the consumer's food and drink experience and often second only to taste, it can be the deciding factor in liking or disliking a product.
From an industry perspective, investing in texture will provide value propositions that satisfy the needs of your consumers, so we need to be able to measure its success when developing or modifying products.
How can we do this? Two ways:
1. Rheology: we describe the sample structure and flow behaviour.
2. Texture Analysis: we study or mimic the act of biting using Texture Profile Analysis (TPA).
It's important to combine the instrumental data which brings a deeper understanding of the structure, with a consumer analysis to provide a more subjective perspective.
We have a full deck on texture studies for food innovation and are happy to discuss in the context of your brand or #npd plans. Reach out to discuss: info@inewtrition.com or send me a PM on LinkedIn.
Texture plays a huge role in the consumer's food and drink experience and often second only to taste, it can be the deciding factor in liking or disliking a product.
From an industry perspective, investing in texture will provide value propositions that satisfy the needs of your consumers, so we need to be able to measure its success when developing or modifying products.
How can we do this? Two ways:
1. Rheology: we describe the sample structure and flow behaviour.
2. Texture Analysis: we study or mimic the act of biting using Texture Profile Analysis (TPA).
It's important to combine the instrumental data which brings a deeper understanding of the structure, with a consumer analysis to provide a more subjective perspective.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
goFLUENT offers distance business English training solutions combining eLearning, Writing Practice and live trainers. Each year goFLUENT helps over 60.000 business executives in more than 5.000 international corporations to make their company more efficient and profitable when doing business globally and managing intercultural situations. goFLUENT is established in 10 countries, with 560 employees – including 400 teachers - and with the world’s third largest telecom company, NTT Communications (NTT Group) owning 30% of its shares. For more information about goFLUENT, please visit http://www.gofluent.com.
Gateway Webinar: Strategies for Biowaiver Application for Generic Nasal Spray...BCNorris Consulting
The active pharmaceutical ingredient (API) size distribution within the final formulation of a drug product is critical as it relates to bioavailability, rates of absorption, and stability of that drug product. Gaining an understanding of the API particle size distribution (PSD) is becoming of greater importance to regulatory agencies, particularly as they relate to the Critical Path Opportunity and biowaiver applications. In fact, a successful ANDA application for mometasone furoate nasal spray utilized Raman spectroscopy as an in vitro study technology in lieu of repeating a clinical endpoint study.
In this webinar, Gateway Analytical will highlight techniques using Raman spectroscopy for abbreviated new drug applications (ANDA) with FDA. Next Breath will present an overview of in vitro bioequivalence requirements and approaches incorporating this new technique.
Analysis using automated Raman technology that combines optical microscopy and Raman spectroscopy will be described. Interpretation of single and agglomerated particles sizes will be presented. In addition, the pros and cons of various instrument approaches will be highlighted. The webinar will conclude with an overview of Gateway’s and Next Breath’s combined strategy for establishing in vitro bioequivalence for regulatory submissions.
Pulmorphix Limited is a start-up company from Liverpool John Moores University (LJMU). We’ve developed what we believe is the world’s first ‘lung biosimulator’ – a device that replicates the conditions deep in the human lung.
We’ve already secured a £82,000 grant from the Technology Strategy Board, the UK Government’s innovation agency.
As well as de-risking the project for investors, we think this is a big vote of confidence both for our technology and our ability to bring it successfully to market.
The Board described the lung biosimulator as “highly innovative and potentially disruptive”, and agreed with us that there is a significant “unmet need” within the pharmaceutical industry.
Using this technology, Pulmorphix intends to offer a commercial testing service to give drug developers a reliable way of understanding how their drugs will behave when inhaled.
Textures of the Future with iNewtritioninewtrition
Texture plays a huge role in the consumer's food and drink experience and often second only to taste, it can be the deciding factor in liking or disliking a product.
From an industry perspective, investing in texture will provide value propositions that satisfy the needs of your consumers, so we need to be able to measure its success when developing or modifying products.
How can we do this? Two ways:
1. Rheology: we describe the sample structure and flow behaviour.
2. Texture Analysis: we study or mimic the act of biting using Texture Profile Analysis (TPA).
It's important to combine the instrumental data which brings a deeper understanding of the structure, with a consumer analysis to provide a more subjective perspective.
We have a full deck on texture studies for food innovation and are happy to discuss in the context of your brand or #npd plans. Reach out to discuss: info@inewtrition.com or send me a PM on LinkedIn.
Texture plays a huge role in the consumer's food and drink experience and often second only to taste, it can be the deciding factor in liking or disliking a product.
From an industry perspective, investing in texture will provide value propositions that satisfy the needs of your consumers, so we need to be able to measure its success when developing or modifying products.
How can we do this? Two ways:
1. Rheology: we describe the sample structure and flow behaviour.
2. Texture Analysis: we study or mimic the act of biting using Texture Profile Analysis (TPA).
It's important to combine the instrumental data which brings a deeper understanding of the structure, with a consumer analysis to provide a more subjective perspective.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
goFLUENT offers distance business English training solutions combining eLearning, Writing Practice and live trainers. Each year goFLUENT helps over 60.000 business executives in more than 5.000 international corporations to make their company more efficient and profitable when doing business globally and managing intercultural situations. goFLUENT is established in 10 countries, with 560 employees – including 400 teachers - and with the world’s third largest telecom company, NTT Communications (NTT Group) owning 30% of its shares. For more information about goFLUENT, please visit http://www.gofluent.com.
Gateway Webinar: Strategies for Biowaiver Application for Generic Nasal Spray...BCNorris Consulting
The active pharmaceutical ingredient (API) size distribution within the final formulation of a drug product is critical as it relates to bioavailability, rates of absorption, and stability of that drug product. Gaining an understanding of the API particle size distribution (PSD) is becoming of greater importance to regulatory agencies, particularly as they relate to the Critical Path Opportunity and biowaiver applications. In fact, a successful ANDA application for mometasone furoate nasal spray utilized Raman spectroscopy as an in vitro study technology in lieu of repeating a clinical endpoint study.
In this webinar, Gateway Analytical will highlight techniques using Raman spectroscopy for abbreviated new drug applications (ANDA) with FDA. Next Breath will present an overview of in vitro bioequivalence requirements and approaches incorporating this new technique.
Analysis using automated Raman technology that combines optical microscopy and Raman spectroscopy will be described. Interpretation of single and agglomerated particles sizes will be presented. In addition, the pros and cons of various instrument approaches will be highlighted. The webinar will conclude with an overview of Gateway’s and Next Breath’s combined strategy for establishing in vitro bioequivalence for regulatory submissions.
Pulmorphix Limited is a start-up company from Liverpool John Moores University (LJMU). We’ve developed what we believe is the world’s first ‘lung biosimulator’ – a device that replicates the conditions deep in the human lung.
We’ve already secured a £82,000 grant from the Technology Strategy Board, the UK Government’s innovation agency.
As well as de-risking the project for investors, we think this is a big vote of confidence both for our technology and our ability to bring it successfully to market.
The Board described the lung biosimulator as “highly innovative and potentially disruptive”, and agreed with us that there is a significant “unmet need” within the pharmaceutical industry.
Using this technology, Pulmorphix intends to offer a commercial testing service to give drug developers a reliable way of understanding how their drugs will behave when inhaled.
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Bill Smith
Brand Acumen's Guide to Online International Non-Proprietary Name (INN) Electronic Name Submission Process.
Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
An introduction to the cryptocurrency investment platform Binance Savings.Any kyc Account
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
2. Case Study: Lantus
The Client: Sanofi-Aventis
Sanofi-Aventis is a diversified global healthcare company that discovers, develops, and dis-
tributes therapeutic solutions to improve the lives of everyone.
The Task: Brand Name Development
The task was to create a global brand name for the first 24-hour long-lasting insulin to come
to market. This allowed patients to only administer one injection per day instead of multiple.
Naming Strategy
In our project kickoff meeting, it was understood that the primary attributes the name should
convey are convenience, reliability, and pioneering.
Name Creation
Our team created an initial list of over 90 potential brand name candidates. This list was nar-
rowed to 8 names after rigorous global linguistic analysis and trademark screening.
Names in Validation Phase
Relipa Laneven Solos
Sangide Ollage
Extine
Glycent Lantus®
@
3. Each of the 8 brand
name finalists was
subjected to
our ScoreCard
analysis,
based on the
following
categories:
Scriptability
Aural Comprehensibility
Visual Aesthetics
Phonetic Viability
Syllabic Balance
Evocative Semantics
Durability & Longevity
Ease of Pronunciation
Gender Properties
Phonemic Simplicity
Case Study: Lantus
@
3
5. 100
50
50
General Practitioners
People with Diabetes
Pharmacists
We interviewed 200 respondents regarding each of the
8 brand name candidates. Respondents included
phy- sicians, pharmacists, and patients.
Case Study: Lantus
QualiQuantitative Interviews
@
5
6. Brand Name Recommendation: Lantus®
Respondents quickly connected with Lantus®. Lantus was noted as future forward (LAN
computing was popular at the time), grounded, regulated, and constant. It’s syllabic and
aural qualities suggest balance and “tus” suffix is a nod to Aventis, the company that
developed it.
Brand Name: Solos
Brand Name Feedback:
Respondents noted that Solos
im-
plied “soluble” as well as
“singular”,
referring to its once daily dosage.
Brand Name: Relipa
Brand Name Feedback:
Respondents noted that Relipa
implied “reliable”. It also
alludes
to recombinant human insulin
and
lipids.
Brand Name: Laneven
Brand Name Feedback:
Laneven served as our secondary
recommendation.Respondents not-
ed feelings of “balance” and
“stabil-
ity” with the brand name candidate
as well as messaging to patients
“even” glucose levels.
Case Study: Lantus
@
6